Patients diagnosed with systemic sclerosis (SSc) may have a three times greater risk of venous thromboembolism (VTE) – including potentially deadly clots in the lungs – and an increased risk in the first year after a diagnosis.
Guselkumab, a selective antagonist of IL-23, went head to head with adalimumab in a year-long phase 2 trial of 293 patients with moderate to severe plaque psoriasis. A quick synopsis of the results here.
(ACR 2014) A drug with a novel mechanism, sifalimumab, shows promise against lupus. In a video interview, Munther Khamastha MD describes the latest research into what could become a second new option for lupus patients.
Positioning of the probe is "three-quarters of the battle" in diagnosing synovitis of the wrist or hand, says Dr. DeMarco in this video. But gel technique and pressure are crucial to gaining accurate clinical information from ultrasound imaging of this condition.
(ACR14) (VIDEO) In tests so far, the infliximab biosimilar BOW015, just approved in India, seems to look about the same to the human immune system as the original. Here, a VP of the company behind BOW015 talks about the realities of seeking approval in the US.
In the second installment of a slide show based on an animated discussion by members of the rheumatology journal club (#rheumjc), partipants focus on the benefits, risks, and realities of tapering biologics in clinical practice.
Slides present key points from a Twitter-based journal club, pondering a randomized study of tapering TNF inhibitors in rheumatoid arthritis. Many questions about the study design. More ask about practices already in use (addressed in Part 2).
Expert rheumatologists examine patterns of treatment failure in gout, in light of six recent guidelines on the condition. This brief slide show based on their review summarizes basics about the guidelines and the clues to optimal treatment, linking to the review itself.
Thrombosis risk is increased in lupus, but not all patients are equal in this regard. This slide show summarizes the key points of a new systematic review on the topic that highlights risk assessment and treatment. Full text is available via hyperlinks in the captions.